1.75
-0.08(-4.37%)
Currency In USD
| Previous Close | 1.83 |
| Open | 1.82 |
| Day High | 1.83 |
| Day Low | 1.72 |
| 52-Week High | 12.51 |
| 52-Week Low | 1.64 |
| Volume | 7.16M |
| Average Volume | 12.85M |
| Market Cap | 584.38M |
| PE | -1.43 |
| EPS | -1.22 |
| Moving Average 50 Days | 2.86 |
| Moving Average 200 Days | 6.86 |
| Change | -0.08 |
If you invested $1000 in Iovance Biotherapeutics, Inc. (IOVA) 10 years ago, it would be worth $163.09 as of June 01, 2025 at a share price of $1.75. Whereas If you bought $1000 worth of Iovance Biotherapeutics, Inc. (IOVA) shares 5 years ago, it would be worth $52.84 as of June 01, 2025 at a share price of $1.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
GlobeNewswire Inc.
May 22, 2025 9:31 PM GMT
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor SAN CAR
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025
GlobeNewswire Inc.
May 02, 2025 8:01 PM GMT
SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
GlobeNewswire Inc.
Apr 23, 2025 8:15 PM GMT
SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patien